- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of Semaglutide
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-07-08
DOI
10.3389/fendo.2021.645563
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study
- (2021) David M. Williams et al. Diabetes Therapy
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
- (2020) Mansoor Husain et al. DIABETES OBESITY & METABOLISM
- Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis
- (2020) Humaira Hussein et al. DIABETES OBESITY & METABOLISM
- Cholelithiasis in patientes treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials
- (2020) Besmir Nreu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of LEADER and SUSTAIN 6 trials
- (2020) Lawrence A. Leiter et al. DIABETES OBESITY & METABOLISM
- Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
- (2020) Charlotte M. Mosterd et al. JOURNAL OF NEPHROLOGY
- Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
- (2020) Olivia R Ghosh-Swaby et al. Lancet Diabetes & Endocrinology
- Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
- (2020) Daisuke Yabe et al. Lancet Diabetes & Endocrinology
- Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
- (2020) Yuichiro Yamada et al. Lancet Diabetes & Endocrinology
- Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial
- (2020) Anne-Marie Langmach Wegeberg et al. United European Gastroenterology Journal
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
- (2020) Apostolos Tsapas et al. ANNALS OF INTERNAL MEDICINE
- Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian LMC diabetes registry ( SPARE study)
- (2020) Ruth E Brown et al. DIABETES OBESITY & METABOLISM
- Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
- (2020) Tito Borner et al. Cell Reports
- Efficacy and safety of once‐weekly semaglutide vs once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes ( SUSTAIN China): a 30‐week double‐blind, phase 3a, randomised trial
- (2020) Linong Ji et al. DIABETES OBESITY & METABOLISM
- Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study
- (2020) Akshay B. Jain et al. Diabetes Therapy
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- (2019) Bernard Zinman et al. Lancet Diabetes & Endocrinology
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Discovery and Development of Liraglutide and Semaglutide
- (2019) Lotte Bjerre Knudsen et al. Frontiers in Endocrinology
- Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features
- (2019) Katherine A. Lyseng-Williamson CLINICAL DRUG INVESTIGATION
- PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
- (2019) Vanita R. Aroda et al. DIABETES CARE
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
- (2019) Richard Pratley et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
- (2019) Thomas R Pieber et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
- (2019) M.S. Capehorn et al. DIABETES & METABOLISM
- Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
- (2019) Michael A. Nauck et al. DIABETES CARE
- Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
- (2019) Bernard Zinman et al. DIABETES CARE
- Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
- (2019) Helena W. Rodbard et al. DIABETES CARE
- The Incremental Risk of Pancreatic Cancer According to Fasting Glucose Levels: Nationwide Population-Based Cohort Study
- (2019) Dong-Hoe Koo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
- (2019) Ildiko Lingvay et al. Lancet Diabetes & Endocrinology
- Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: The AngioSafe type 2 diabetes study
- (2019) Bénédicte Gaborit et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
- (2018) Ippei Ikushima et al. ADVANCES IN THERAPY
- Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
- (2018) Kohei Kaku et al. DIABETES OBESITY & METABOLISM
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- (2018) Bo Ahrén et al. DIABETES OBESITY & METABOLISM
- Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial
- (2018) Stefan Korsatko et al. DIABETES OBESITY & METABOLISM
- Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
- (2018) Tina Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity
- (2018) Christina C. Nexøe-Larsen et al. DIABETES OBESITY & METABOLISM
- Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
- (2018) Helena W Rodbard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
- (2018) Michal Witkowski et al. Diabetes Therapy
- No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
- (2018) Valentin Demmel et al. Diabetes Therapy
- A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
- (2018) Michal Witkowski et al. Diabetes Therapy
- No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
- (2018) Valentin Demmel et al. Diabetes Therapy
- P2857Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial
- (2018) J Seufert et al. EUROPEAN HEART JOURNAL
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
- (2018) Charlotte Granhall et al. CLINICAL PHARMACOKINETICS
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
- (2018) Stephen T. Buckley et al. Science Translational Medicine
- A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
- (2018) Irene Romera et al. Diabetes Therapy
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study
- (2017) Bonnie C. Shaddinger et al. JOURNAL OF CLINICAL PHARMACOLOGY
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
- (2017) Laurie L. Baggio et al. Molecular Metabolism
- Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males
- (2016) Mark M. Smits et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
- (2016) Preman Kumarathurai et al. DIABETES CARE
- Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial
- (2016) Mark M. Smits et al. DIABETES CARE
- Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas
- (2016) M. M. Smits et al. DIABETES OBESITY & METABOLISM
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
- (2016) Karolin Bettge et al. DIABETES OBESITY & METABOLISM
- Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients
- (2016) Mark M. Smits et al. DIABETES OBESITY & METABOLISM
- Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial
- (2016) Mark M Smits et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database
- (2016) V. Pizzimenti et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?
- (2016) Dora M. Gorman et al. Diabetes & Metabolism Journal
- Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability
- (2015) Yuki Nakatani et al. DIABETES CARE
- Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes
- (2015) Jennifer S. ten Kulve et al. DIABETES CARE
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates
- (2014) C. F. Gotfredsen et al. DIABETES
- Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes
- (2014) Julie A. Lovshin et al. DIABETES CARE
- Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas
- (2014) Beatrice Waser et al. MODERN PATHOLOGY
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
- (2014) L. Li et al. BMJ-British Medical Journal
- A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
- (2013) D. Funch et al. DIABETES OBESITY & METABOLISM
- A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes
- (2013) Hirotake Tokuyama et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice
- (2013) J. H. Ellenbroek et al. DIABETOLOGIA
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- (2013) M E J Lean et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
- (2013) Sonal Singh et al. JAMA Internal Medicine
- Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study
- (2013) Carlo B Giorda et al. Lancet Diabetes & Endocrinology
- The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis
- (2012) Niels Vrang et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
- (2012) Changting Xiao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Investigation of the haemodynamic effects of exenatide in healthy male subjects
- (2012) Buddhike Mendis et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model
- (2012) Belinda Gier et al. DIABETES
- The Human GLP-1 Analog Liraglutide and the Pancreas
- (2012) Niels C.B. Nyborg et al. DIABETES
- No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
- (2012) K. Tatarkiewicz et al. DIABETES OBESITY & METABOLISM
- Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
- (2012) M. Wenten et al. DIABETIC MEDICINE
- Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors in the Outpatient Setting
- (2012) Howard Lando et al. Endocrine Practice
- The Glucagon-Like Peptide-1 Receptor—or Not?
- (2012) Charles Pyke et al. ENDOCRINOLOGY
- Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
- (2012) Jutta Keller et al. REGULATORY PEPTIDES
- A cohort study of acute pancreatitis in relation to exenatide use
- (2011) D. D. Dore et al. DIABETES OBESITY & METABOLISM
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
- (2011) Belinda Gier et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia*
- (2010) Adam M. Deane et al. CRITICAL CARE MEDICINE
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
- (2010) R. Garg et al. DIABETES CARE
- Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects
- (2010) C. Ellero et al. DIABETIC MEDICINE
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
- (2010) Alfonso López-Ruiz et al. PHARMACY WORLD & SCIENCE
- Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study
- (2009) R. A. Noel et al. DIABETES CARE
- Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
- (2009) J. S. Nachnani et al. DIABETOLOGIA
- Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans
- (2008) Adil E. Bharucha et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis
- (2008) M Marzioni et al. GUT
- Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
- (2008) Helle Linnebjerg et al. REGULATORY PEPTIDES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now